Study of Survival Duration for Donor Skin Cells in Skin Biopsy Wounds

• HP802-247 (Biological): One dose of HP802-247 consisting off 260 mL containing keratinocytes and fibroblasts totaling 5.0 x 10.6 cells per mL, plus fibrin.

Primary outcomes

• Identification of the Full Set of Y-chromosome Short Tandem Repeats in Each Bioopsy. [Cohorts of 3 subjects were biopsied at weekly intervals for 8 weeks]: The primary efficacy variable was detection of the full set of 17 Y STR loci. If all loci amplified such that a clear identification of a donor was possible, the test result was categorized as positive. If fewer loci amplified such that identification of the donor was not possible in a forensic setting, the result was categorized as negative. Descriptive statistics are presented for this variable.

Secondary outcomes

• Time in Days to 50% Correct Identification (ID50) of the Implanted Male DNA 17 Loci in Female Volunteers, With Regard to Three DNA Profile Types, Including Partial DNA Profile, > 50% DNA Profile, and Full (or Complete) DNA Profile. [Cohorts of 3 subjects were biopsied at weekly intervals for 8 weeks]: The biopsy area was examined for the presence of the Y chromosome, based on the presence of a full set of Y-STR loci as well as partial sets, assayed by a commercial kit (AmpFISTRTM). Probit analysis was utilized to determine the time in days to 50% correct identification (ID50) of the implanted male DNA 17 loci in female volunteers, with regard to three DNA profile types, including partial DNA profile, > 50% DNA profile, and full (or complete) DNA profile. The analysis was performed using SAS® PROC PROBIT

Sex: Female, ages: 18 Years to any, accepts healthy volunteers

Inclusion Criteria:

* Provide written informed consent.
* Female, 18 years of age or older.
* Any race or skin type, provided that there are no tattoos within 5 cm of the wound target, and the gentian violet surgical marker produces a clearly visible mark on the skin.
* Willing to make all required study visits and, in the opinion of the Investigator, able to follow instructions.
* Willing to undergo the repeated biopsy procedures.
* Willing to undergo verification of sex chromosome status.

Exclusion Criteria:

* Males, or phenotypic females bearing Y-chromosome genetic material \[e.g., 46,X,(r)Y; 46,X,der(X)t(X;Y); sex reassignment surgery\].
* Contraindications or hypersensitivity to the use of the study medications or their components (e.g., history of anaphylaxis, serum sickness, or erythema multiforme reaction to aprotinin, bovine serum albumin or bovine serum proteins, penicillin, streptomycin, or amphotericin B).
* History of keloid formation or hypertrophic scarring.
* Participation in any interventional clinical trial within 30 days prior to screening.
* History of prolonged bleeding, bleeding into joints, easy bruising following minor trauma, clotting factor deficiency, or current use of anticoagulants or platelet inhibitors.
* Any medical condition which, in the opinion of the Co-Investigator, may interfere with normal wound repair.
* Current therapy with drugs or biologics intended to function as immuno-suppressants, chronic (> 10 days) oral corticosteroids, or any concomitant medication which, in the opinion of the Co-Investigator, may interfere with normal wound repair.

Participant flow

Outcome results

• Identification of the Full Set of Y-chromosome Short Tandem Repeats in Each Bioopsy. (Primary), Count of participants, Participants: HP802-247 3
• Time in Days to 50% Correct Identification (ID50) of the Implanted Male DNA 17 Loci in Female Volunteers, With Regard to Three DNA Profile Types, Including Partial DNA Profile, > 50% DNA Profile, and Full (or Complete) DNA Profile. (Secondary), Number, Days: HP802-247 19 (0 to 30)

Adverse events

Time frame: Safety reporting occurred over the eight weeks of the study.

Serious adverse events by term

Other adverse events by term

• Herbert B Slade, MD, Study chair, Healthpoint, Ltd
• Barry Reece, MS, Principal investigator, RCTS, Inc.